Heart Failure With Reduced Ejection Fraction Clinical Trial
— INITIATEOfficial title:
Initiation of Angiotensin Receptor-neprilysin Inhibitor (ARNi) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): the INITIATE-HFrEF Randomized Open-label Trial
Heart failure (HF) is a condition in which the heart does not contract ("pump") or relax well, leading to insufficient perfusion of vital organs. Ankle swelling, fatigue, and breathlessness are some of the features of this syndrome. There are different causes for HF (e.g., infarct and hypertension) and two distinct types: HFpEF - HF with preserved ejection fraction - the heart "pumps" but does not relax well and HFrEF/HFmrEF - HF with reduced or mildly reduced ejection fraction - where the heart does not "pump" properly. Patients with HFrEF experience substantially shorter life expectancies compared with people in the general population of similar age. Compared to the different available therapeutics for HFrEF patients, angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan, has shown superiority for improving clinical outcomes. Furthermore, the new recently drug sodium-glucose cotransporter 2 inhibitor (SGLT2i) was proven to reduce mortality and morbidity on top of well-adapted background therapy. This work aims to test the safety of ARNi and SGLT2i initiation by comparing a strategy of simultaneous initiation of ARNi and SGLT2i versus sequential initiation of a SGLT2i first followed by an ARNi.
Status | Recruiting |
Enrollment | 172 |
Est. completion date | February 2025 |
Est. primary completion date | November 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 years 2. Heart failure symptoms (NYHA II, III or IV) 3. Left ventricle ejection fraction = 49% (assessed by transthoracic echocardiogram) 4. Glomerular filtration rate = 25 ml/min/1.73m2 (CKD-EPI formula) 5. Serum potassium (K+) = 5.4 mmol/L 6. Systolic blood pressure = 100 mmHg 7. Not treated with ARNi nor with SGLT2i within the previous month (30 days before inclusion, except if initiated 5 days before randomization) 8. If female, she must not be a woman of childbearing potential. That is, she must be: 1. Surgically sterilized (e.g., underwent hysterectomy, bilateral salpingectomy or bilateral oophorectomy) 2. Clinically diagnosed infertile 3. In a post-menopausal state, defined as no menses for 12 months without an alternative medical cause 9. If female patient of childbearing potential, she must have a negative serum pregnancy test at Visit 1 (Day 0) and must agree to consistently and correctly use (from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration) one of the following highly effective methods of contraception: 1. Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject) 2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) 3. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) 4. Intrauterine device 5. Intrauterine hormone-releasing system 6. Bilateral tubal occlusion 7. Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner Exclusion Criteria: 1. Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site) 2. Participation in another clinical study with an investigational product during the last month 3. Unwilling to sign inform consent 4. Patients with a known hypersensitivity or intolerance to ARNi or SGLT2i or any of the excipients of the products 5. Hospitalization due to non-cardiovascular causes, surgical procedure, coronary, cerebral or peripheral vascular events or sepsis in the prior month 6. Cancer (life limiting with an estimated life expectancy of less than 2 years based on investigator's judgement) 7. Previously confirmed cardiac amyloidosis 8. History of angioedema 9. Implantable cardioverter-defibrillators or cardiac resynchronization therapy within 3 months prior to screening or if there is an intent to implant either device in the 3 months following screening 10. Female patients currently pregnant (confirmed by a positive pregnancy test) or intent to become pregnant or breast feeding 11. Severe valvulopathy according to the echocardiogram report 12. Previous history of ketoacidosis due to SGLT2i |
Country | Name | City | State |
---|---|---|---|
Portugal | Centro Hospitalar Universitário de Santo António | Porto | |
Portugal | Centro Hospitalar Universitário São João | Porto | |
Portugal | Centro Hospitalar Vila Nova de Gaia/Espinho | Porto | |
Portugal | Faculty of Medicine (FMUP) | Porto | |
Portugal | Unidade Local de Saúde de Matosinhos - Hospital Pedro Hispano | Porto |
Lead Sponsor | Collaborator |
---|---|
Universidade do Porto | Faculty of Medicine (FMUP), Rede de Investigação em Saúde (RISE), Laboratório Associado, Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC) |
Portugal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite outcome (time-to-first event' occurrence during the 6 months of follow-up): | Symptomatic hypotension (systolic blood pressure <100 mmHg with signs or symptoms compatible with hypoperfusion);
Hyperkalaemia (serum potassium >6.0 mmol/L); Hypokalemia (serum potassium <3.0 mmol/L); eGFR drop =50% from baseline or eGFR <15 ml/min/1.73m2 or renal transplant or dialysis; Increase in diuretic dose due to worsening heart failure; Use of intravenous diuretics for worsening heart failure; Heart failure hospitalization; Death from cardiovascular causes. |
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Symptomatic hypotension (systolic blood pressure <100 mmHg with signs or symptoms compatible with hypoperfusion) | Time to event' occurrence during the 6 months of follow-up | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Hyperkalaemia (serum potassium >6.0 mmol/L) | Time to event' occurrence during the 6 months of follow-up | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Hypokalemia (serum potassium <3.0 mmol/L) | Time to event' occurrence during the 6 months of follow-up | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | eGFR drop =50% from baseline or eGFR <15 ml/min/1.73m2 or renal transplant or dialysis | Time to event' occurrence during the 6 months of follow-up | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Increase in diuretic dose due to worsening heart failure | Time to event' occurrence during the 6 months of follow-up | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Use of intravenous diuretics for worsening heart failure | Time to event' occurrence during the 6 months of follow-up | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Heart failure hospitalization | Time to event' occurrence during the 6 months of follow-up | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Death from cardiovascular causes | Time to event' occurrence during the 6 months of follow-up | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | NT-pro BNP or BNP (log) | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | High sensitivity C-reactive protein | Concentration measured in blood samples | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Atrial fibrillation/flutter | Electrocardiogram (yes/no) | visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Systolic and diastolic blood pressure | Measure in the clinical appointments | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | High sensitivity Troponin | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Left atrial volume | Transthoracic echocardiogram | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Left ventricular systolic volume | Transthoracic echocardiogram | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Left ventricular diastolic volume | Transthoracic echocardiogram | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | LV mass | Transthoracic echocardiogram | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | LV ejection fraction | Transthoracic echocardiogram | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Pulmonary artery systolic pressure | Transthoracic echocardiogram | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Serum sodium | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Serum potassium | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Serum creatinine | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Glomerular filtration rate (eGFR) | Calculated from the serum creatinine using the 2021 CKD-EPI creatinine-based formula | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Urinary sodium | Spot urine sample | visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Urinary potassium | Spot urine sample | visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Microalbuminuria | Spot urine sample | visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Total Cholesterol | Concentration measured in blood samples | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | LDL Cholesterol | Concentration measured in blood samples | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | HDL Cholesterol | Concentration measured in blood samples | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Triglycerides | Concentration measured in blood samples | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Glucose | Measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Glycated hemoglobin (HbA1C) | Concentration measured in blood samples | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Uric acid | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | TSH | Concentration measured in blood samples | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | Free thyroxin | Concentration measured in blood samples | visit 1 (day 0); visit 4 (visit 3 + 90±15 days) | |
Secondary | ALAT | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | ASAT | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Gamma-GT | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Alkaline Phosphatase | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Total bilirubin | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Serum iron | Concentration measured in blood samples | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Ferritin | Concentration measured in blood samples | visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Transferrin saturation | Concentration measured in blood samples | visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Functional class (NYHA, New York Heart Association) | Assessed by the medical doctors in the clinical appointments (I / II / III / IV) | visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Quality of life (KCCQ, Kansas City Cardiomyopathy Questionnaire) | HR-QoL assessed by the Kansas City Cardiomyopathy Questionnaire a 12-item instrument. All items are measured on a Likert scale with 5-7 response options. KCCQ scores are scaled from 0 to 100 and summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent | visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days) | |
Secondary | Dosage titration of sacubitril/valsartan up to the dose 97/103 mg (b.i.d.) at 3 months | Assessed by the medical doctors in the clinical appointments | visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Completed |
NCT03614169 -
Direct HIS-pacing as an Alternative to BiV-pacing in Symptomatic HFrEF Patients With True LBBB
|
N/A | |
Recruiting |
NCT05278962 -
HF Patients With LVADs Being Treated With SGLT2i
|
Phase 4 | |
Completed |
NCT04210375 -
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
|
Phase 1 | |
Not yet recruiting |
NCT06433687 -
Evaluation of the HekaHeart Platform in Medication Management for Heart Failure Patients
|
||
Completed |
NCT05001165 -
Dashboard Activated Services and Tele-Health for Heart Failure
|
N/A | |
Active, not recruiting |
NCT03701880 -
Early Use of Ivabradine in Heart Failure
|
N/A | |
Recruiting |
NCT05650658 -
Left vs Left Randomized Clinical Trial
|
N/A | |
Not yet recruiting |
NCT06299436 -
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
|
||
Recruiting |
NCT05992116 -
Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
|
||
Recruiting |
NCT05365568 -
Left Bundle Branch Area Pacing for Cardiac Resynchronization Therapy: A Randomized Study
|
N/A | |
Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
Not yet recruiting |
NCT04420065 -
Effects of Preferential Left Ventricular Pacing on Ventriculoarterial Coupling and Clinical Course of Heart Failure
|
N/A | |
Terminated |
NCT03479424 -
Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
|
||
Completed |
NCT02113033 -
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
|
Phase 2 | |
Recruiting |
NCT03209180 -
Immediate Release Versus Slow Release Carvedilol in Heart Failure
|
Phase 4 | |
Recruiting |
NCT05299879 -
Screening for Advanced Heart Failure IN Stable ouTpatientS - The SAINTS Study
|
||
Recruiting |
NCT05637853 -
Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction
|
||
Completed |
NCT03870074 -
CPET Predicts Long-term Survival and Positive Response to CRT
|
||
Recruiting |
NCT04590001 -
Effect of the MobiusHD® in Patients With Heart Failure
|
N/A |